N/A N=30 Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device
Asthma
Primary: Safety- Number of Participants With Adverse Events — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response Following Principle Investigator Review — 23.2 percentage of participants
Phase 3 N=285 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Nasal Cavity
Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68
Phase 2 N=80 Pembrolizumab +/- Bevacizumab for Recurrent GBM
Glioblastoma
Primary: Pembrolizumab Maximum Tolerated Dose (MTD) [Cohort A Safety Lead-In] — 200 mg every 3 weeks
Phase 3 N=836 Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
Pulmonary Disease, Chronic Obstructive
Primary: Rate of Moderate or Severe Exacerbations in Participants in the High Stratum — 1.71; 1.40 Moderate/severe exacerbations per year — p==0.036
Phase 2 N=15 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase — 15; 5 Participants
Phase 3 N=708 Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Open-angle Glaucoma · Ocular Hypertension
Primary: IOP (Intraocular Pressure) — 23.93; 23.89; 22.67; 22.77 mmHg
Phase 3 N=24 Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
Severe Hemophilia A
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) as Measured by One-stage Activated Partial Thromboplastin Time (aPTT) Clotting Assay for…
Phase 3 N=956 Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
Arthritis, Rheumatoid
Primary: Modified Total Sharp Score (mTSS) at Month 6 — 20.50; 18.85; 17.54 score on a scale
Phase 3 N=756 Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Ocular Hypertension · Open-angle Glaucoma
Primary: Intraocular Pressure (IOP) — 23.51; 23.45; 23.50; 22.31 mmHg
Phase 3 N=674 Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Rate of Moderate or Severe Exacerbations — 1.49; 1.19; 1.27 Moderate/severe exacerbations per year — p=0.068
Phase 3 N=215 Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization
Infertility · Ovulation Induction · In-Vitro Fertilization
Primary: Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) — 159 subjects
Phase 2 N=46 Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel
Pain · Peripheral Neuropathy
Primary: Worst of the Pain Scores for the Week Following the First Cycle of Paclitaxel Administration, Paclitaxel-associated Acute Pain Syndrome (P-APS) Pain Score — 2.6; 3.2…
Phase 2 N=150 Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Lung Cancer · Non Small Cell Lung Carcinoma
Primary: Number of Participants With Objective Response Assessed by Independent Review Committee — 2; 8; 1 participants
Phase 3 N=1,176 Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis (SAR)
Primary: Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS) — 10.3; 10.1; 10.2; 10.2 units on a scale — p=<0.001